Matching articles for "natalizumab"
Issue 1680 · July 10, 2023
Drugs for Inflammatory Bowel Disease

Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have…

Med Lett Drugs Ther. 2023 Jul 10; 65(1680):105-12 doi:10.58347/tml.2023.1680a
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Issue 1671 · March 6, 2023
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis

The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):36-8 doi:10.58347/tml.2023.1671c
The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC ofatumumab (Kesimpta) , are also FDA-approved for these indications.
Issue 1630 · August 9, 2021
Ponesimod (Ponvory) for Multiple Sclerosis

The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):123-5
The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients ≥10 years old.
Issue 1620 · March 22, 2021
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations,…

Med Lett Drugs Ther. 2021 Mar 22; 63(1620):42-8
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Issue 1605 · August 24, 2020
Ozanimod (Zeposia) for Multiple Sclerosis

The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):132-4
The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third oral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod (Mayzent) is also indicated for use in adults, and fingolimod (Gilenya) is approved for use in patients ≥10 years old.
Issue 1577 · July 29, 2019
Cladribine (Mavenclad) for Multiple Sclerosis

The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):118-20
The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of MS. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS.
Issue 1571 · May 6, 2019
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis

The FDA has approved siponimod ( Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically…

Med Lett Drugs Ther. 2019 May 6; 61(1571):70-2
The FDA has approved siponimod ( Mayzent – Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod is the second S1P receptor modulator to be approved in the US; fingolimod (Gilenya) , which is approved for oral treatment of relapsing forms of MS in patients ≥10 years old, was the first. The purine antimetabolite cladribine (Mavenclad) was also recently approved for oral treatment of relapsing forms of MS and will be reviewed in a future issue.
Issue 1550 · July 2, 2018
Drugs for Inflammatory Bowel Disease

Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection.…

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):107-14
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Issue 1550 · July 2, 2018
Table: Drugs for Crohn's Disease (online only)

View Table: Drugs for Crohn's Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e115
View Table: Drugs for Crohn's Disease
Issue 1550 · July 2, 2018
Table: Safety of Drugs for IBD in Pregnancy (online only)

View Table: Safety of Drugs for IBD in Pregnancy

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e116
View Table: Safety of Drugs for IBD in Pregnancy
Issue 1550 · July 2, 2018
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)

View Expanded Table: Some Drugs for Inflammatory Bowel Disease

Med Lett Drugs Ther. 2018 Jul 2; 60(1550):e117-22
View Expanded Table: Some Drugs for Inflammatory Bowel Disease
Issue 1523 · June 19, 2017
Ocrelizumab (Ocrevus) for MS

The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):98-101
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Issue 1511 · January 2, 2017
Ustekinumab (Stelara) for Crohn's Disease

The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):5-6
The FDA has approved the human interleukin (IL)-12 and -23 antagonist ustekinumab ( Stelara – Janssen Biotech) for treatment of moderately to severely active Crohn's disease in adults who were intolerant of or whose disease was unresponsive to treatment with immunomodulators or corticosteroids, or a tumor necrosis factor (TNF) inhibitor. Ustekinumab was approved earlier for treatment of psoriasis and psoriatic arthritis.
Issue 1503 · September 12, 2016
Daclizumab (Zinbryta) for Multiple Sclerosis

The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):117-9
The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the first subcutaneously injected monoclonal antibody to be approved for treatment of MS.
Issue 1496 · June 6, 2016
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):71-4
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.
Issue 1468 · May 11, 2015
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis

The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).

Med Lett Drugs Ther. 2015 May 11; 57(1468):67-9
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
Issue 1451 · September 15, 2014
Vedolizumab (Entyvio) for Inflammatory Bowel Disease

The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to,…

Med Lett Drugs Ther. 2014 Sep 15; 56(1451):86-8
The FDA has approved vedolizumab ( Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri) , another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.
Issue 1448 · August 4, 2014
Drugs for Inflammatory Bowel Disease

Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is…

Med Lett Drugs Ther. 2014 Aug 4; 56(1448):65-72
Aminosalicylates are effective for induction and maintenance of remission in mild to moderate ulcerative colitis. They are not recommended for treatment of Crohn's disease. FORMULATIONS — Oral mesalamine is rapidly absorbed in the small intestine and most of the drug does not reach the colon. Pentasa releases mesalamine gradually throughout the gastrointestinal tract. Delzicol , Asacol HD , Lialda , and Apriso delay the release of the drug until it reaches the distal ileum and colon. Sulfasalazine ( Azulfidine , and generics), balsalazide ( Colazal , and others), and olsalazine (Dipentum) are prodrugs; mesalamine is azo-bonded to a second moiety and released in the colon following bacterial cleavage of the bond. Mesalamine is also available as an enema (Rowasa , and generics) and as a rectal suppository (Canasa) .
Issue 1418 · June 10, 2013
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis

The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years…

Med Lett Drugs Ther. 2013 Jun 10; 55(1418):45-7
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
Issue 1403 · November 12, 2012
New Drugs for Multiple Sclerosis

In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second…

Med Lett Drugs Ther. 2012 Nov 12; 54(1403):89-91
In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second oral drug to be approved by the FDA for treatment of relapsing forms of MS.
Issue 115 · March 1, 2012
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of…

Treat Guidel Med Lett. 2012 Mar; 10(115):19-28
Inflammatory bowel disease (IBD) is generally classified as either Crohn’s disease (CD) or ulcerative colitis (UC). More detailed guidelines on their treatment are available from the American College of Gastroenterology.
Issue 1353 · December 13, 2010
Oral Fingolimod (Gilenya) for Multiple Sclerosis

The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of…

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):98-100
The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of multiple sclerosis (MS). Fingolimod is the first oral drug approved for this indication.
Issue 1350 · November 1, 2010
Interferon Beta-1b (Extavia) for Multiple Sclerosis

The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the…

Med Lett Drugs Ther. 2010 Nov 1; 52(1350):86-7
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the same factory and packaged separately.
Issue 1347 · September 20, 2010
Dalfampridine (Ampyra) for MS

The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):73-4
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a reliable clinical measure of impairment in patients with MS.
Issue 85 · September 1, 2009
Drugs for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is…

Treat Guidel Med Lett. 2009 Sep; 7(85):65-74
Inflammatory bowel disease (IBD) is either Crohn's disease or ulcerative colitis. Drug selection is guided by disease type (Crohn's versus ulcerative colitis), severity and location and whether the goal is induction or maintenance of remission. Table 1 on page 66 lists the drugs used to treat IBD with their formulations and cost. Table 2 on page 68 lists the drugs of choice and their doses for different indications. Table 3 on page 71 lists the drugs' adverse effects and recommendations for monitoring. More detailed guidelines are available from the American College of Gastroenterology.
Issue 1307 · March 9, 2009
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis

Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):17-8
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Issue 1287 · June 2, 2008 Free
Correction: Natalizumab (Tysabri) for Crohn's Disease

The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement:…

Med Lett Drugs Ther. 2008 Jun 2; 50(1287):44
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to [emphasis added] death or the need for a liver transplant in some patients." Also, in the last sentence of the Conclusion, we should have said: "Because of the risk of serious hepatic toxicity and the rare but even more serious risk of developing progressive multifocal leukoencephalopathy, it should be used only in patients who have not responded to other drugs, including a TNF inhibitor." The italicized words should be substituted for "it is FDA-approved for use." Download: U.S. English
Issue 1285 · May 5, 2008
Natalizumab (Tysabri) for Crohn's Disease

Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors…

Med Lett Drugs Ther. 2008 May 5; 50(1285):34-6
Natalizumab ( Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF). Initially approved in 2004 for the treatment of multiple sclerosis (MS), natalizumab was temporarily withdrawn from the market after 3 patients developed progressive multifocal leukoencephalopathy (PML). It is now available for treatment of both MS and CD through a restricted distribution program.
Issue 1243 · September 11, 2006 Free
In Brief: Natalizumab (Tysabri) Returns

Soon after The Medical Letter first reviewed use of natalizumab ( Tysabri – Biogen Idec and Elan) for treatment of relapsing forms of multiple sclerosis (MS) (Med Lett Drugs Ther 2005; 47:13) , the drug was…

Med Lett Drugs Ther. 2006 Sep 11; 48(1243):76
Soon after The Medical Letter first reviewed use of natalizumab ( Tysabri – Biogen Idec and Elan) for treatment of relapsing forms of multiple sclerosis (MS) (Med Lett Drugs Ther 2005; 47:13) , the drug was withdrawn from the market. The unpublished clinical trials that led to its approval by the FDA have since been published, and now the drug has been returned to the market with prescribing restrictions. Natalizumab decreases the number of relapses and new brain lesions in patients with MS. It was withdrawn because progressive multifocal leukoencephalopathy (PML) occurred in 3 (of about 3000) patients being treated with the drug; two were taking the drug in combination with interferon beta for MS, and one was taking it with azathioprine for Crohn’s disease. PML is an opportunistic infection of the brain, caused by reactivation of the JC virus in immunosuppressed patients, that often causes death or severe neurological disability. There is no treatment for PML. The publication of the natalizumab clinical trials in MS provided information on the drug’s effect on the progression of disability, which was not available when it was first reviewed here. In one study, combination therapy with natalizumab and interferon beta-1a for 2 years led to an estimated cumulative probability of progression of 23%, compared to 29% with interferon beta-1a alone (RA Rudick et al. N Engl J Med 2006; 354:911) . In the second study, the estimated cumulative probability of progression over 2 years was 17% with natalizumab alone and 29% with placebo (CH Polman et al. N Engl J Med 2006; 354:899) . Download U.S. English
Issue 1204 · March 14, 2005 Free
In Brief: Natalizumab (Tysabri) Withdrawn

The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21
The February 14th issue of The Medical Letter reviewed natalizumab ( Tysabri - Biogen Idec), a new monoclonal antibody that was granted accelerated approval because it decreased the number of relapses in patients with multiple sclerosis. On February 28th, the FDA issued a Public Health Advisory announcing that marketing of the drug had been suspended because 2 patients who had been treated with natalizumab for more than 2 years had developed progressive multifocal leukoencephalopathy, a rare, often fatal disease (www.fda.gov) .
Issue 1202 · February 14, 2005
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and…

Med Lett Drugs Ther. 2005 Feb 14; 47(1202):13-5
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.